Specific laboratory test have proven the effectiveness of the Billy-CAB

The persistence of the Covid-19 pandemic over time, as well as the need to protect the medical operators involved in the transport of highly contagious patients, requires the use of biocontainment devices.
After designing the Billy-CAB – high-performance biocontainment system – STEM has been the first company to carry out specific tests to verify the effectiveness of the products.

How the effectiveness of the biocontainment has been proven

The tests have verified the number of particles in the medical compartment of an ambulance equipped with the Billy-CAB system. To do so, we used an aerosol system to simulate the human breathing activity: the device was programmed to release 2,6 µm particles, the same dimensions of droplets containing infectious microorganisms. Then, we placed three particle counters in strategic points inside the vehicle:

  • At patient’s head end, nearby the ventilation unit at a height of 850 mm from the ground;
  • Near the stretcher at 700 mm from the ground;
  • At patient’s feet end.

Moreover, to simulate the real conditions of stretcher loading and unloading, measures have been taken with the Billy-CAB on and off, with bonnet open and close.

Results: no infected particles in the medical compartment

The results achieved have exceeded expectations. Using the biocontainment system Billy-CAB, there are almost no particles in the medical compartment. The ventilation unit, operating to maintain negative pressure inside the device, generates air flow that conveys the particles towards the Hepa filter placed at patient’s head end. So the operators are assured a safe transport environment with no pathogens and with constant air monitoring.
The tests carried out on the Billy-CAB system have allowed Stem to provide a further guarantee of the efficacy and high performance of its product, reaffirming once again its vocation for innovation in the medical transport devices field.